Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:56:14 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:THTX from 2023-04-27 to 2024-04-26 - 54 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-15 16:15U:THTXNews ReleaseTheratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
2024-04-11 07:30U:THTXNews ReleaseTheratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
2024-04-10 07:30U:THTXNews ReleaseTheratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
2024-04-08 16:30U:THTXNews ReleaseTheratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology(TM) Oncology Platform
2024-04-05 11:00U:THTXNews ReleaseTheratechnologies Appoints Elina Tea to its Board of Directors
2024-04-03 07:30U:THTXNews ReleaseTheratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
2024-03-28 07:30U:THTXNews ReleaseTheratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology(TM) Platform
2024-03-22 09:36U:THTXNews ReleaseTheratechnologies Announces Update on its Preclinical Oncology Research Program
2024-03-21 20:00U:THTXNews ReleaseTheratechnologies Appoints Jordan Zwick to its Board of Directors
2024-03-21 07:30U:THTXNews ReleaseTheratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
2024-02-29 16:34U:THTXNews ReleaseTheratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
2024-02-27 07:30U:THTXNews ReleaseTheratechnologies Receives Refusal to File Letter for Trogarzo(TM) Intramuscular Method of Administration sBLA from FDA
2024-02-21 07:30U:THTXNews ReleaseTheratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
2024-02-20 07:30U:THTXNews ReleaseTheratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
2024-02-15 07:30U:THTXNews ReleaseTheratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
2024-02-06 07:30U:THTXNews ReleaseTheratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
2024-01-24 07:00U:THTXNews ReleaseTheratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
2024-01-23 07:30U:THTXNews ReleaseTheratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
2024-01-02 07:30U:THTXNews ReleaseTheratechnologies Submits sBLA for Trogarzo ‚ ® Intramuscular (IM) Method of Administration to FDA
2023-12-21 16:09U:THTXNews ReleaseTheratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
2023-12-21 16:09U:THTXNews ReleaseTheratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
2023-12-13 07:30U:THTXNews ReleaseTheratechnologies Announces FDA Approval of Trogarzo ‚ ® 90-Second Intravenous (IV) Push Loading Dose
2023-11-24 07:30U:THTXNews ReleaseTheratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
2023-10-31 12:34U:THTXNews ReleaseTheratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
2023-10-26 08:00U:THTXNews ReleaseTheratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
2023-10-25 16:13U:THTXNews ReleaseTheratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement
2023-10-24 07:00U:THTXNews ReleaseTheratechnologies Announces Operational Update
2023-10-19 07:30U:THTXNews ReleaseTheratechnologies ¢ € ™ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
2023-10-16 07:30U:THTXNews ReleaseTheratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
2023-10-13 07:30U:THTXNews ReleaseTheratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
2023-10-13 07:00U:THTXNews ReleaseTheratechnologies Announces Results from Trogarzo ‚ ® (Ibalizumab-uiyk) Intramuscular Administration Study
2023-10-12 07:30U:THTXNews ReleaseTheratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
2023-10-04 07:30U:THTXNews ReleaseTheratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
2023-09-26 07:30U:THTXNews ReleaseTheratechnologies Reports Financial Results ‚  for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
2023-09-25 07:30U:THTXNews ReleaseTheratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
2023-09-25 07:00U:THTXNews ReleaseTheratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
2023-09-20 07:00U:THTXNews ReleaseTheratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
2023-09-18 16:15U:THTXNews ReleaseTheratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
2023-09-07 13:58U:THTXNews ReleaseTheratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-09-05 07:00U:THTXNews ReleaseTheratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights
2023-08-30 10:35U:THTXNews ReleaseTheratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide
2023-07-31 07:00U:THTXNews ReleaseTheratechnologies Completes 1-for-4 Reverse Stock Split
2023-07-28 16:45U:THTXNews ReleaseTheratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management
2023-07-21 07:00U:THTXNews ReleaseTheratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn
2023-07-20 07:00U:THTXNews ReleaseTheratechnologies Announces 1-for-4 Reverse Stock Split
2023-07-12 07:30U:THTXNews ReleaseTheratechnologies Reports Second Quarter 2023 Financial Results and Business Updates
2023-06-29 07:30U:THTXNews ReleaseTheratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
2023-06-22 07:30U:THTXNews ReleaseTheratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management
2023-06-12 07:30U:THTXNews ReleaseTheratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial
2023-06-02 12:16U:THTXNews ReleaseTheratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
2023-05-25 17:31U:THTXNews ReleaseTheratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
2023-05-19 17:11U:THTXNews ReleaseEarly Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc.
2023-05-09 12:02U:THTXNews ReleaseTheratechnologies Reports on its Annual Meeting of Shareholders
2023-05-04 07:30U:THTXNews ReleaseTheratechnologies ¢ € ™ Trogarzo ‚ ® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison